Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Financing › Details

Cellectis–SEVERAL: investment, 201706–201707 Calyxt IPO $64.4m w 7m+1.05m common shares at $8/share Cellectis retains 79.9% shareholding


Period Period 2017-06-23 ï¿½ 2017-07-25
Region Region United States (USA)
Organisations Money taker Calyxt Inc. (Nasdaq Global Market: CLXT)
  Group Cellectis (Group)
  Money source SEVERAL
Products Product genome editing (gene editing)
  Product 2 investment banking

Cellectis S.A.. (7/25/17). "Press Release: Calyxt Announces Full Exercise of Over-allotment Option and Closing of Its Initial Public Offering". St. Paul, MN & New York, NY.

Cellectis S.A. (NASDAQ: CLLS) and Calyxt, Inc. (NASDAQ: CLXT) announced today the closing of Calyxt’s initial public offering of 8,050,000 shares of its common stock at the initial public offering price of $8.00 per share (the “Offering”). The number of shares issued in the Offering includes the exercise in full of the underwriters’ option to purchase up to 1,050,000 additional shares. Calyxt received approximately $64.4 million in proceeds from the offering, before deducting underwriting fees and estimated offering expenses. Calyxt’s shares of common stock are traded on the NASDAQ Global Market under the symbol “CLXT”.

Calyxt is Cellectis’ gene editing agriculture company. Cellectis owns approximately 79.9% of Calyxt’s outstanding shares of common stock. Citigroup, Jefferies and Wells Fargo Securities acted as joint book-running managers for the proposed offering. BMO Capital Markets and Ladenburg Thalmann acted as co-managers.

A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission. A copy of the final prospectus relating to this Offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146, Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at, or Wells Fargo Securities, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York, 10152, at (800) 326-5897 or by email at

The final prospectus is also available at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further information, please contact:

Media contacts

Jennifer Moore, VP Communications
Phone: 917-580-1088
email: /

Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
Phone: 212-896-1241 / 212-896-1206
email: /

Investor Relations contact

Simon Harnest, VP Corporate Strategy and Finance
Phone: 646-385-9008

Record changed: 2017-11-25


Picture [iito] Männer Ballett 650x80px

More documents for Cellectis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top